Solara Active Pharma Sciences Ltd Q4 FY25 Results & Concall Highlights: Revenue, Margins & Order Book

Published 15 Jul 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹2.4K Cr

The company expects a top-line revenue growth of around 10% for FY '26. The company expects a top-line revenue growth of around 10% in FY '26.

From Solara Active Pharma Sciences Ltd's Q4 FY25 earnings-call transcript · updated 23 Aug 2026.

Price

₹617

Market Cap

₹2.4K Cr

P/E Ratio

573.4

How does Solara Active Pharma Sciences Ltd rank in Pharmaceuticals & Biotechnology?

Compare Solara Active Pharma Sciences Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Solara Active Pharma Sciences Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹387 Cr, net profit ₹10 Cr.

Full financials →

📊 Revenue & Sales Performance

→The company expects a top-line revenue growth of around 10% for FY '26.
→EBITDA is projected to grow by 15% to 20% in FY '26, driven by gross margin expansion and operating cost leverage.
→Quarter-on-quarter sales growth is anticipated to start from Q1 FY '26.
→The growth focus is on higher-margin products, especially ibuprofen derivatives and non-ibuprofen products, reducing reliance on plain ibuprofen.
→Capacity utilization currently stands at 60%, indicating room for volume growth.
→Incremental capital investment is planned, especially for the Vizag plant to onboard new customers, which may support future volume growth.
→The company aims to pivot from a reset phase to growth phase, emphasizing profitable growth with continued market expansion and operating cost optimization.

📈 Profitability & Margins

→The company expects a top-line revenue growth of around 10% in FY '26.
→EBITDA is projected to grow between 15% to 20% in FY '26, outpacing revenue growth due to operating cost reductions and gross margin expansion.
→Margin expansion is driven by improved product mix, focusing less on low-margin plain ibuprofen and more on higher-margin derivatives and non-ibuprofen products.
→Capacity utilization currently stands at 60%, indicating room for operational leverage to boost profitability as utilization rises.
→Interest costs are expected around INR 85 crores for the year, with efforts to reduce finance costs by approximately 200 basis points going forward.
→The company plans to maintain depreciation expense at around INR 99 crores for modeling purposes.
→Net debt-to-EBITDA ratio is targeted to decline to approximately 1.7-1.8 by Q1 FY '27, with further reduction to 1.5 post demerger and debt pushdown to a new CRAMS and polymer entity, aiding profitability.
→Growth in the CDMO business and Vizag plant is expected but currently at early stages with modest near-term growth (10-15%).

🏗️ Capital Expenditure Plans

- The company has not yet started putting capital in the Vizag plant for onboarding customers. (Page 12) - There is small expected growth (10%-15%) from the Vizag plant, but onboarding customers is pending capital investment. (Page 12) - The company is building incremental capacities to debottleneck higher-margin products, indicating ongoing capacity expansions. (Page 5) - Discussions on capital investments related to the CDMO (CRAMS) business are underway, and more specifics will be shared closer to the scheme and NCLT process. (Page 10 and 13) - A planned carve-out of the CRAMS and polymer entity will involve the pushdown of close to INR 200 crores debt, which may indicate strategic structural investment. (Page 6) - The management mentioned ongoing efforts on cost improvements and operational optimizations linked with growth and margin expansion, likely involving strategic investments. (Pages 4, 6) No explicit large-scale new capex figures or timelines given beyond these points.

💰 Fundraising & Capital Structure

→The company has ongoing rights issue with first call money already received and expected to be utilized soon, which will reduce debt to around INR647 crores by end of May 2025.
→A second call money of the rights issue is expected to be realized by May 2026.
→Post realization of the second call money, and subject to shareholder and statutory approvals for the new CRAMS and polymer entity demerger, the company plans to push down debt of close to INR200 crores to the new entity.
→This restructuring should make the catalog business balance sheet lighter and reduce net debt-to-EBITDA ratio to approximately 1.5 times.
→No explicit mention of new fundraising through fresh debt or equity beyond the ongoing rights issue and restructuring is present in the call transcript.

📋 Order Book & Pipeline

The transcript provided does not explicitly mention the current or expected order book or pending orders details for Solar Active Pharma Sciences Limited. However, some relevant points related to business outlook and operations are: - The company expects a top-line growth of around 10% in FY '26 with EBITDA growth between 15%-20%. - Capital investments at the Vizag plant have not yet started, so customer onboarding there has not begun, implying limited orders currently from that facility. - The company is focusing on growth in higher-margin products and shifting away from plain ibuprofen towards derivatives and non-ibuprofen products. - CDMO business is currently small (~INR100 crores) and still in planning stages for future growth. - Management aims to improve capacity utilization (currently at ~60%) and expects quarter-on-quarter sales growth starting Q1 FY '26. No specific numbers on order book or pending orders are disclosed in the call.

Key Metrics

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Biocon (Q4 FY25)
FY'25 saw a consolidation and transition phase setting up for accelerated growth, with a 10% YoY increase in revenue and 16% YoY growth in core EBITDA (Page…
Natural Capsules (Q4 FY25)
196 crore, implying about Rs. Key concall takeaways from Natural Capsules Ltd's Q4 FY25 earnings call — and how it ranks against sector peers.
Laurus Labs (Q4 FY25)
Capex of around INR1,000 crore planned for FY26 primarily to expand CDMO/CMO capacities, with minimal increase in debt. Key concall takeaways from Laurus Labs…
Wockhardt Ltd (Q4 FY25)
EBITDA growth: Recorded a 67% increase in the last year, with EBITDA margins expanding by 500 basis points from 9% to 14%. Key concall takeaways from Wockhardt…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

Frequently Asked Questions

What were Solara Active Pharma Sciences Ltd Q4 FY25 results?

The company expects a top-line revenue growth of around 10% for FY '26. The company expects a top-line revenue growth of around 10% in FY '26.

What is Solara Active Pharma Sciences Ltd share price analysis?

Solara Active Pharma Sciences Ltd currently shows a neutral. The stock trades at a P/E of 573.4 with a market cap of ₹2,448 Cr. Investors should review the full earnings analysis for detailed insights.

Is Solara Active Pharma Sciences Ltd planning capital expenditure?

The company has not yet started putting capital in the Vizag plant for onboarding customers.

Keep Solara Active Pharma Sciences Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.